查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984092

基因編輯技術市場：按技術平台、遞送方式、疾病和應用分類的全球市場預測 – 2026-2032 年

Gene Editing Technologies Market by Technology Platform, Delivery Method, Disease Indication, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，基因編輯技術市值將達到 205.9 億美元，到 2026 年將成長至 231.7 億美元，到 2032 年將達到 540.8 億美元，複合年成長率為 14.78%。

主要市場統計數據
基準年 2025 205.9億美元
預計年份：2026年 231.7億美元
預測年份 2032 540.8億美元
複合年成長率 (%) 14.78%

對現代基因編輯進行簡要概述，重點介紹技術進步、實用化的勢頭以及各領域相關人員的戰略考慮因素。

過去十年，基因編輯技術已從一項前景看好的實驗室技術發展成為變革生物醫學研究、農業科學和工業生物技術的基礎工具。核酸酶設計、遞送系統和編輯精度的進步，使研究人員能夠以前所未有的解析度分析生物系統。同時，臨床計畫和轉化研究正穩步從概念驗證邁向治療應用階段。因此，各領域的相關人員正在重新評估其投資組合、投資重點和合作模式，以最大限度地發揮這些平台的科學和商業性潛力。

編輯化學、遞送方法和監管合作的最新技術突破如何重塑創新路徑和商業性夥伴關係。

基因編輯正經歷一場變革性的轉型，這得益於精準化學技術的進步、模組化平台架構的建構以及連接髮現與應用的成熟生態系統的發展。近期技術突破凸顯了鹼基編輯和先導編輯技術的進步，這些技術減少了對雙鏈機制的依賴，從而提高了特異性並拓展了治療標靶的範圍。同時，諸如TALEN、ZFN和Meganucleases技術等傳統平台的持續改進，在那些對標靶性和智慧財產權要求極高的領域，依然展現出獨特的優勢。

對於從事基因編輯研究和生產的組織而言，評估關稅政策的變化如何重塑供應鏈、籌資策略和跨境業務運作至關重要。

貿易和關稅體系的政策變化會對研究材料、供應鏈以及基因編輯創新轉化為可操作解決方案的經濟效益產生連鎖反應。影響試劑、定序耗材、病毒載體組成或專用設備的關稅可能成為籌資策略中的摩擦點，迫使各機構重新評估其採購、庫存和供應商多元化策略。因此，實驗室和製造商可能需要調整供應商合約和物流安排，以確保營運的連續性並維持研究處理能力。

將平台特性、交付方式、應用領域和最終用戶需求連結起來的細分市場分析，有助於策略優先排序和產品定位。

細分市場層面的差異對於理解技術能力如何與應用需求和最終用戶需求交織至關重要。從平台角度來看，CRISPR、Meganucleases、TALEN 和 ZFN 之間的差異對標靶選擇、智慧財產權策略和生產流程具有重要意義。在 CRISPR 內部，鹼基編輯、Cas9 和先導編輯等​​子平台各自具有不同的優點和缺點。鹼基編輯減少了對雙鏈的依賴，並根據不同的突變情況細分為基於腺嘌呤和基於胞嘧啶的編輯模式。另一方面，先導編輯無需供體模板即可擴展可實現的精確編輯範圍。

區域比較趨勢凸顯了美洲、歐洲、中東和非洲以及亞太地區在轉化能力、監管方法和商業機會方面的差異。

區域趨勢持續對基因編輯的研究、開發和實用化應用產生重大影響。在美洲，轉化研究、創業投資和臨床基礎設施的優勢為加速治療計畫和擴大生產能力創造了有利條件。此外，該地區擁有緊密的合約研究機構和專業服務公司網路，能夠支持從藥物發現到臨床檢驗的快速迭代。

獨特的平台、合作結構和製造能力如何決定整個基因編輯生態系統的競爭優勢和夥伴關係策略。

基因編輯領域的競爭格局是由專有平台、合作聯盟和垂直整合策略共同塑造的。掌握差異化編輯技術和遞送平台的機構通常利用授權協議、共同開發夥伴關係和策略採購來擴大自身影響力，同時保持其核心技術優勢。同時，服務供應商和受託研究機構在降低研發過程中的風險方面發揮著至關重要的作用，它們提供臨床前試驗、載體生產和法規遵從支援方面的專業知識。

領導者可以採取切實可行的策略和營運步驟，以協調平台選擇、交付最佳化、供應鏈彈性和相關人員協作，從而確保永續的競爭優勢。

領導者應採取務實的投資組合策略，平衡平台開發、應用導向投資和營運韌性。首先，應優先考慮與組織優勢相符的技術路線。在機制方面擁有深厚專業知識的組織可以投資改進起始基因和基礎基因編輯，而那些擁有成熟病毒載體能力的組織則可以專注於最佳化夥伴關係和生產效率。同時，應透過有針對性的合作以及在研發規劃早期整合轉化終點指標，加強交付和安全性評估能力。

採用透明的混合方法研究設計，結合專家訪談、文獻整合和情境測試，以檢驗有關平台、應用程式和營運的推論。

支持這些發現的研究結合了系統性文獻綜述、專家訪談以及對技術和應用領域進展的結構化分析。關鍵工作包括與轉化科學家、臨床開發經理、生產專家和商業負責人進行對話，以收集關於技術限制、監管參與和營運重點的第一手觀點。此外，還使用了包括同行評審文章、監管指導文件和技術白皮書在內的二手資訊來評估平台功能和交付方式。

整合各組織必須協調的科學、營運和政策要求，以便將基因編輯的進步轉化為治療、農業和工業的具體成果。

基因編輯正處於一個關鍵的十字路口，技術進步、遞送創新以及不斷變化的監管和政策環境在此交匯，既創造了新的機遇，也帶來了切實的營運挑戰。精準編輯化學的進步和多樣化的遞送方法拓展了基因編輯的應用範圍，使其從治療項目擴展到農業和工業領域。同時，地緣政治因素、供應鏈脆弱性以及公眾對安全性和透明度日益成長的期望，都要求各組織採取綜合策略，將卓越的科學技術與前瞻性的營運能力結合。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按技術平台分類的基因編輯技術市場

  • CRISPR
    • 基礎編輯
      • 腺嘌呤鹼基編輯
      • 胞嘧啶鹼基編輯
    • Cas9
    • 主編
  • Meganucleases
  • TALEN
  • ZFN

第9章：基因編輯技術市場：以交付方式分類

  • 非病毒
    • 電穿孔
    • 脂質奈米顆粒
    • 顯微注射
  • 病毒性的
    • 腺結合病毒
    • 慢病毒
    • 逆轉錄病毒

第10章 基因編輯技術市場：依疾病適應症分類

  • 感染疾病
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固體癌
  • 罕見遺傳疾病
    • 囊腫纖維化
    • 鐮狀細胞貧血症

第11章 基因編輯技術市場：依應用領域分類

  • 農業
    • 農作物
    • 家畜
  • 工業的
    • 生質燃料
    • 生質塑膠
  • 研究工具
    • 偵測
    • 細胞株工程
    • 圖書館篩檢
  • 治療
    • Ex Vivo
      • 免疫療法
      • 幹細胞療法
    • In vivo
      • 細胞株基因編輯
      • 體細胞基因編輯

第12章 基因編輯技術市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 基因編輯技術市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 基因編輯技術市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國基因編輯技術市場

第16章：中國基因編輯技術市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • AMS Biotechnology Ltd.
  • Beam Therapeutics Inc.
  • Caribou Biosciences, Inc.
  • Cellectis SA
  • Creative Biogene
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • GenScript Biotech Corporation
  • Horizon Discovery Ltd.
  • Inscripta, Inc.
  • Integrated DNA Technologies, Inc.
  • Intellia Therapeutics, Inc.
  • Lonza Group Ltd.
  • Mammoth Biosciences, Inc.
  • Merck Group
  • New England Biolabs, Inc.
  • OriGene Technologies, Inc.
  • Precision BioSciences, Inc.
  • Sangamo Therapeutics, Inc.
  • Synthego Corporation
  • Takara Bio Inc.
  • Tecan Trading AG
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-2E76C3E47FBE

The Gene Editing Technologies Market was valued at USD 20.59 billion in 2025 and is projected to grow to USD 23.17 billion in 2026, with a CAGR of 14.78%, reaching USD 54.08 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 20.59 billion
Estimated Year [2026] USD 23.17 billion
Forecast Year [2032] USD 54.08 billion
CAGR (%) 14.78%

A succinct orientation to contemporary gene editing that outlines technological advances, translational momentum, and strategic considerations for stakeholders across sectors

The past decade has seen gene editing evolve from a promising laboratory technique into a foundational tool reshaping biomedical research, agricultural science, and industrial biotechnology. Advances in nuclease design, delivery systems, and editing precision have enabled researchers to interrogate biological systems with unprecedented resolution, while clinical programs and translational pipelines have moved increasingly from conceptual demonstration toward therapeutic application. As a result, stakeholders across disciplines are recalibrating portfolios, investment priorities, and collaborative models to capture the scientific and commercial potential of these platforms.

This introduction synthesizes the current landscape by focusing on the converging technical advances and ecosystem dynamics that matter to executives and R&D leaders. It highlights the interplay between platform innovation and downstream application, the growing importance of delivery and safety considerations, and the shifting expectations around regulatory dialogues and public acceptance. By foregrounding these themes, the narrative sets a pragmatic foundation for subsequent sections that address structural shifts, policy impacts, segmentation intelligence, regional patterns, and actionable recommendations for organizations seeking to navigate the gene editing frontier.

How recent technical breakthroughs in editing chemistry, delivery modalities, and regulatory engagement are recalibrating innovation pathways and commercial collaborations

Gene editing is undergoing transformative shifts driven by refinements in precision chemistry, modular platform architectures, and a maturing ecosystem that links discovery to application. Recent technical milestones have emphasized base editing and prime editing modalities that reduce reliance on double-strand break mechanisms, thereby improving specificity and broadening the set of treatable targets. At the same time, incremental improvements in traditional platforms such as TALEN, ZFN, and meganuclease technologies continue to offer niche advantages where bespoke targeting or intellectual property considerations prevail.

Concurrently, the landscape is changing as delivery innovations-ranging from lipid nanoparticle formulations to viral vector engineering-reshape how therapies reach target tissues and how agricultural or industrial edits are deployed. This nexus of platform sophistication and delivery robustness is catalyzing new partnerships between biotechnology developers, contract research providers, and advanced manufacturing specialists. Moreover, ethical and regulatory discourse has intensified, prompting more proactive engagement between developers and regulators to define acceptable risk thresholds and clinical endpoints. Together, these shifts are creating an environment where iterative technical improvement and pragmatic governance combine to accelerate translational pathways and broaden the practical reach of gene editing applications.

Assessing how evolving tariff policies reshape supply chains, procurement strategies, and cross-border operational choices for entities engaged in gene editing research and production

Policy changes in trade and tariff regimes can have cascading effects on research inputs, supply chains, and the economics of translating gene editing innovations into deployable solutions. Tariffs that affect reagents, sequencing consumables, viral vector components, or specialized equipment create friction points in procurement strategies, forcing organizations to reassess sourcing, inventory, and vendor diversification. In turn, laboratories and manufacturers may alter supplier contracts and logistics arrangements to preserve continuity of operations and maintain research throughput.

Beyond procurement, tariffs can influence strategic decisions such as location of preclinical manufacturing, choices about in-house versus outsourced capabilities, and the structuring of cross-border collaborations. Academic centers, contract research organizations, and biopharmaceutical developers may respond by consolidating key operations in tariff-favored jurisdictions or by deepening partnerships with regional suppliers. Importantly, these adjustments often lead to increased emphasis on supply chain visibility and risk management, with teams investing in scenario planning and buffer strategies. In aggregate, tariff dynamics reshape the operational calculus for organizations engaging in gene editing R&D and production, underscoring the need for adaptable sourcing frameworks and proactive commercial planning.

Segment-focused analysis linking platform characteristics, delivery choices, application domains, and end-user needs to inform strategic prioritization and product positioning

Segment-level differentiation is central to understanding where technical capabilities intersect with application demand and end-user needs. On the platform side, distinctions among CRISPR, meganuclease, TALEN, and ZFN are consequential for target selection, intellectual property strategy, and manufacturing workflows. Within CRISPR, sub-platforms such as Base Editing, Cas9, and Prime Editing offer distinct trade-offs: Base Editing reduces double-strand break reliance and is subdivided into Adenine Base Editing and Cytosine Base Editing modalities that address different mutational contexts, while Prime Editing expands the range of precise edits that can be achieved without donor templates.

Application segmentation further clarifies use cases, spanning Agricultural pursuits with crops and livestock applications, Industrial uses focused on biofuels and bioplastics, Research Tools encompassing assays, cell line engineering, and library screening, and Therapeutic development that separates Ex Vivo approaches-such as immunotherapy and stem cell therapy-from In Vivo strategies, which include germline and somatic editing. End users vary accordingly; large and small biopharmaceutical companies, clinical and preclinical contract research organizations, clinics and hospitals within medical centers, and academic research groups and government laboratories each demand different data packages, regulatory support, and commercialization roadmaps. Delivery method choices between Nonviral techniques like electroporation, lipid nanoparticle formulations, and microinjection, and Viral vectors such as adeno-associated virus, lentivirus, and retrovirus, influence development timelines, scalability, and safety profiles. Disease indication prioritization, including infectious diseases, oncology with its hematological and solid tumor subcategories, and rare genetic disorders such as cystic fibrosis and sickle cell disease, shapes clinical endpoints and patient recruitment strategies. Together, these segmentation vectors provide a multidimensional framework for aligning technology selection, development pathways, and commercial tactics with specific organizational goals.

Comparative regional dynamics that highlight differentiated translational capacity, regulatory approaches, and operational opportunities across the Americas, EMEA, and Asia-Pacific

Regional dynamics continue to exert a strong influence on the trajectory of gene editing research, development, and deployment. In the Americas, strengths in translational research, venture capital formation, and clinical infrastructure create favorable conditions for accelerating therapeutic programs and scaling manufacturing capabilities. This regional ecosystem also hosts a dense network of contract research providers and specialized service firms that support rapid iteration from discovery to clinical validation.

The Europe, Middle East & Africa region presents a heterogeneous landscape in which robust academic ecosystems and well-developed regulatory frameworks coexist with jurisdictions that are still building advanced manufacturing and clinical trial capacity. Policy variability across countries requires careful navigation, yet the region's emphasis on ethical oversight and patient safety frequently leads to close regulatory engagement and high standards for clinical evidence. In the Asia-Pacific region, expanding biotechnology talent pools, growing manufacturing capacity, and proactive industrial strategies have led to intensified activity across both therapeutic and agricultural applications. Cross-border partnerships, regional supply chains, and investments in next-generation facilities characterize this area, creating options for organizations seeking operational redundancy and cost-effective production. These regional patterns underscore the necessity of tailoring commercialization strategies, regulatory approaches, and partner selection to the specific strengths and constraints of each geography.

How proprietary platforms, alliance structures, and manufacturing capabilities define competitive advantage and partnership strategies across the gene editing ecosystem

Competitive dynamics in the gene editing landscape are shaped by a combination of proprietary platforms, collaborative alliances, and vertical integration strategies. Organizations that control differentiated editing modalities or delivery platforms frequently leverage licensing arrangements, co-development partnerships, and strategic sourcing to extend their reach while retaining core technological advantages. Concurrently, service providers and contract research organizations play a pivotal role in de-risking development pathways by offering specialized capabilities in preclinical testing, vector manufacturing, and regulatory support.

Intellectual property management, manufacturing scale-up, and clinical trial design are recurring battlegrounds where firms seek durable advantages. Companies with integrated manufacturing capabilities can accelerate timelines and exert greater control over quality, whereas those focused on platform refinement may rely on partnerships to commercialize downstream applications. Additionally, cross-sector collaborations that combine academic discovery with commercial development continue to be a fertile source of innovation, particularly when they address translational bottlenecks such as delivery, immunogenicity mitigation, and long-term safety monitoring. For decision-makers, understanding how prospective partners or rivals configure these capabilities is essential when evaluating alliance fit, outsourcing decisions, and in-licensing opportunities.

Practical strategic and operational steps leaders can implement to align platform choices, delivery optimization, supply chain resilience, and stakeholder engagement for durable advantage

Leaders should adopt a pragmatic portfolio approach that balances platform development with application-focused investments and operational resilience. Begin by prioritizing technology routes that align with institutional strengths: organizations with deep mechanistic expertise may invest in prime editing or base editing refinement, while those with established viral vector competencies might focus on optimizing tropism and manufacturing throughput. Simultaneously, strengthen delivery and safety assessment capabilities through targeted partnerships and by integrating translational endpoints early in development planning.

Operationally, diversify supply chains and engage in scenario planning to mitigate tariff-related and geopolitical risks. Contractual arrangements that incorporate dual sourcing, regional manufacturing options, and inventory buffering will reduce exposure to procurement disruptions. On the commercial front, cultivate relationships with clinical networks, payers, and patient advocacy groups to ensure that development programs reflect realistic clinical pathways and adoption considerations. Finally, invest in regulatory engagement and ethical communications to build trust with stakeholders and streamline approvals. By executing on these interconnected actions, institutions can better position themselves to translate technical advances into durable clinical, agricultural, or industrial outcomes.

A transparent mixed-method research design that integrates expert interviews, literature synthesis, and scenario testing to validate platform, application, and operational inferences

The research underpinning these insights combined systematic literature review, expert interviews, and structured analysis of technology and application trajectories. Primary engagements included conversations with translational scientists, clinical development leads, manufacturing experts, and commercial strategists to capture first-hand perspectives on technical constraints, regulatory interactions, and operational priorities. Secondary sources consisted of peer-reviewed publications, regulatory guidance documents, and technical white papers that informed assessments of platform capabilities and delivery approaches.

To ensure rigor, the methodology emphasized triangulation across data types and stakeholders, cross-checking claims about platform performance against empirical evidence from preclinical and early clinical studies, and validating operational inferences through practitioner feedback. Scenario analysis was used to explore the implications of policy shifts and supply chain disruptions, while segmentation logic was constructed to reflect the practical decision nodes that organizations face when selecting platforms, applications, delivery methods, and end-user targets. This mixed-method approach produced a structured evidence base that supports actionable recommendations while maintaining transparency about limits and assumptions.

Synthesis of the scientific, operational, and policy imperatives that organizations must reconcile to translate gene editing advances into tangible therapeutic, agricultural, and industrial outcomes

Gene editing stands at a pivotal juncture where technical progress, delivery innovation, and evolving regulatory and policy environments converge to create new opportunities and real operational challenges. Advances in precision editing chemistries and diversified delivery methods have expanded the range of feasible applications from therapeutic programs to agricultural and industrial uses. At the same time, geopolitical factors, supply chain fragility, and heightened expectations for safety and transparency demand that organizations adopt integrated strategies that combine scientific excellence with operational foresight.

Moving forward, sustained progress will require coordinated investment in delivery science, robust engagement with regulatory and ethical stakeholders, and flexible commercial strategies that reflect regional differences and end-user needs. Organizations that successfully navigate this landscape will be those that marry deep technical capabilities with pragmatic supply chain and partnership choices, and who prioritize the translational steps needed to move from laboratory promise to real-world impact. The conclusion underscores the importance of aligning internal capabilities with external realities to realize the full potential of gene editing technologies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gene Editing Technologies Market, by Technology Platform

  • 8.1. CRISPR
    • 8.1.1. Base Editing
      • 8.1.1.1. Adenine Base Editing
      • 8.1.1.2. Cytosine Base Editing
    • 8.1.2. Cas9
    • 8.1.3. Prime Editing
  • 8.2. Meganuclease
  • 8.3. TALEN
  • 8.4. ZFN

9. Gene Editing Technologies Market, by Delivery Method

  • 9.1. Nonviral
    • 9.1.1. Electroporation
    • 9.1.2. Lipid Nanoparticle
    • 9.1.3. Microinjection
  • 9.2. Viral
    • 9.2.1. Adeno Associated Virus
    • 9.2.2. Lentivirus
    • 9.2.3. Retrovirus

10. Gene Editing Technologies Market, by Disease Indication

  • 10.1. Infectious Diseases
  • 10.2. Oncology
    • 10.2.1. Hematological Malignancies
    • 10.2.2. Solid Tumors
  • 10.3. Rare Genetic Disorders
    • 10.3.1. Cystic Fibrosis
    • 10.3.2. Sickle Cell Disease

11. Gene Editing Technologies Market, by Application

  • 11.1. Agricultural
    • 11.1.1. Crops
    • 11.1.2. Livestock
  • 11.2. Industrial
    • 11.2.1. Biofuels
    • 11.2.2. Bioplastics
  • 11.3. Research Tools
    • 11.3.1. Assays
    • 11.3.2. Cell Line Engineering
    • 11.3.3. Library Screening
  • 11.4. Therapeutic
    • 11.4.1. Ex Vivo
      • 11.4.1.1. Immunotherapy
      • 11.4.1.2. Stem Cell Therapy
    • 11.4.2. In Vivo
      • 11.4.2.1. Germline Gene Editing
      • 11.4.2.2. Somatic Gene Editing

12. Gene Editing Technologies Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Gene Editing Technologies Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Gene Editing Technologies Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Gene Editing Technologies Market

16. China Gene Editing Technologies Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. AMS Biotechnology Ltd.
  • 17.7. Beam Therapeutics Inc.
  • 17.8. Caribou Biosciences, Inc.
  • 17.9. Cellectis SA
  • 17.10. Creative Biogene
  • 17.11. CRISPR Therapeutics AG
  • 17.12. Editas Medicine, Inc.
  • 17.13. GenScript Biotech Corporation
  • 17.14. Horizon Discovery Ltd.
  • 17.15. Inscripta, Inc.
  • 17.16. Integrated DNA Technologies, Inc.
  • 17.17. Intellia Therapeutics, Inc.
  • 17.18. Lonza Group Ltd.
  • 17.19. Mammoth Biosciences, Inc.
  • 17.20. Merck Group
  • 17.21. New England Biolabs, Inc.
  • 17.22. OriGene Technologies, Inc.
  • 17.23. Precision BioSciences, Inc.
  • 17.24. Sangamo Therapeutics, Inc.
  • 17.25. Synthego Corporation
  • 17.26. Takara Bio Inc.
  • 17.27. Tecan Trading AG
  • 17.28. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENE EDITING TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENE EDITING TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GENE EDITING TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GENE EDITING TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENINE BASE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENINE BASE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENINE BASE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYTOSINE BASE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYTOSINE BASE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYTOSINE BASE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CAS9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CAS9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CAS9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRIME EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRIME EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRIME EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEGANUCLEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEGANUCLEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEGANUCLEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TALEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TALEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TALEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ZFN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ZFN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ZFN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RETROVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RETROVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RETROVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SICKLE CELL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SICKLE CELL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SICKLE CELL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CROPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CROPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CROPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOFUELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOFUELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPLASTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPLASTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPLASTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CELL LINE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CELL LINE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CELL LINE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIBRARY SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIBRARY SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIBRARY SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GERMLINE GENE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GERMLINE GENE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GERMLINE GENE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOMATIC GENE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOMATIC GENE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOMATIC GENE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 278. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 288. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 289. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 290. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 292. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 296. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 298. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 299. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 300. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 301. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 302. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 303. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 304. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 305. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 306. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 307. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 308. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 309. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 310. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 311. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 312. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)

TABLE 315.